Leon Tung, MD
Critical Care Medicine · Tyler, TXNPI 1700171287
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Johnson & Johnson at 37.8% of the total. Reporting peaked in 2022 at $2,353 and has fallen 95.8% since, to $99 in 2025.
Across 81 payments — averaging $61.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Intuitive Surgical$932
- AstraZeneca$778
- GSK$399
- Boehringer Ingelheim$199
- Gilead$116
- plus $658 from 14 others
Across 4 payments — averaging $9517.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$38K
What the payments were for
- Travel & lodging$2,74355%
- Food & beverage$2,06842%
- Education$1423%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 7 | $1,871 |
| Intuitive Surgical | 4 | $932 |
| AstraZeneca | 16 | $778 |
| GSK | 21 | $399 |
| Boehringer Ingelheim | 9 | $199 |
| Gilead | 1 | $116 |
| Harmony Biosciences LLC | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Sanofi | 3 | $85 |
| Philips North America LLC | 1 | $52 |
| United Therapeutics Corporation | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 1 | $48 |
| Inogen, Inc. | 5 | $44 |
| Baxter Healthcare | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Mylan Specialty L.p. | 2 | $29 |
| Fisher & Paykel Healthcare Inc | 1 | $27 |
| Grifols USA, LLC | 1 | $24 |
| Insmed, Inc. | 1 | $17 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$1,811
- Da Vinci Surgical System$913
- FASENRA$211
- Veklury$116
- TEZSPIRE$116
- NUCALA$101
- Wakix$100
How this compares
$4,953 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $156,747 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 171 | $121,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $64,360 |
| TezspireTezepelumab-Ekko | 16 | $62,317 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $7,801 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 173 | $5,387 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,646 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $4,025 |
| DuleraMometasone/Formoterol | 12 | $3,763 |
| Ventolin HfaAlbuterol Sulfate | 33 | $1,872 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,297 |
| Mycophenolate Mofetil | 15 | $985 |
| Montelukast Sodium | 71 | $565 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $554 |
| Fluticasone Propionate | 39 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $778 | $191,339213 claims |
| Boehringer IngelheimOfev | $199 | $156,74712 claims |
| GSKTrelegy Ellipta | $399 | $64,36060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Tyler
- David JonesTyler$9K
- Steven DavidoffPlano$364K
- William BartekAustin$284K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
- Anthony OrtegonDallas$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.